Nonetheless, these vulnerabilities cannot be extrapolated to all KRAS contexts, and it is necessary to continue exploring KRAS-related pathways within a specific tumor context to understand their implications for cancer initiation, progression and therapy. The gene discussed is KRAS; the disease is cancer.